Overview Remepy has published new mechanistic findings in npj Parkinson’s Disease demonstrating how Hybridopa, its Hybrid Drug for Parkinson’s disease, may improve ...
Overview Remepy announced positive Phase IIa results for Hybridopa, its Hybrid Drug combining levodopa with an AI-driven digital therapeutic, demonstrating significant improvement...
Overview Remepy has entered a collaboration with Merck KGaA, Darmstadt, Germany, to explore the development of Hybrid Drugs that combine pharmacological therapies with AI-enabled digital th...
